Download MendeleyMaturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody.
Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M.G., Ozorowski, G., Chuang, G.Y., Schramm, C.A., Wiehe, K., Alam, S.M., Bradley, T., Gladden, M.A., Hwang, K.K., Iyengar, S., Kumar, A., Lu, X., Luo, K., Mangiapani, M.C., Parks, R.J., Song, H., Acharya, P., Bailer, R.T., Cao, A., Druz, A., Georgiev, I.S., Kwon, Y.D., Louder, M.K., Zhang, B., Zheng, A., Hill, B.J., Kong, R., Soto, C., Mullikin, J.C., Douek, D.C., Montefiori, D.C., Moody, M.A., Shaw, G.M., Hahn, B.H., Kelsoe, G., Hraber, P.T., Korber, B.T., Boyd, S.D., Fire, A.Z., Kepler, T.B., Shapiro, L., Ward, A.B., Mascola, J.R., Liao, H.X., Kwong, P.D., Haynes, B.F.(2016) Cell 165: 449-463
- PubMed: 26949186
- DOI: https://doi.org/10.1016/j.cell.2016.02.022
- Primary Citation of Related Structures:
5F96, 5F9O, 5F9W - PubMed Abstract:
Antibodies with ontogenies from VH1-2 or VH1-46-germline genes dominate the broadly neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with longitudinal sampling from time-of-infection the development of a VH1-46-derived antibody lineage that matured to neutralize 90% of HIV-1 isolates. Structures of lineage antibodies CH235 (week 41 from time-of-infection, 18% breadth), CH235.9 (week 152, 77%), and CH235.12 (week 323, 90%) demonstrated the maturing epitope to focus on the conformationally invariant portion of the CD4bs. Similarities between CH235 lineage and five unrelated CD4bs lineages in epitope focusing, length-of-time to develop breadth, and extraordinary level of somatic hypermutation suggested commonalities in maturation among all CD4bs antibodies. Fortunately, the required CH235-lineage hypermutation appeared substantially guided by the intrinsic mutability of the VH1-46 gene, which closely resembled VH1-2. We integrated our CH235-lineage findings with a second broadly neutralizing lineage and HIV-1 co-evolution to suggest a vaccination strategy for inducing both lineages.
Organizational Affiliation:
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
